Abstract
Summary
The global Nucleic acid isolation and purification market is projected to reach USD 9.4 billion by 2028 from USD 6.4 billion in 2023, at a CAGR of 8.1% during the forecast period. The factors responsible for the growth of this market include increasing automation, growing research and development activities and increasing technological advancements.
In 2022, the kits segment accounted for the largest share of the global nucleic acid isolation and purification market.
Based on products, the nucleic acid isolation and purification market has been segmented into kits, reagents, and instruments. The instruments segment is further segmented into automatic and manual instruments. In 2022, the kits segment accounted for the largest share of the global nucleic acid isolation and purification market. Factors responsible for the growth in this market include easy usage and cost of kits in applications including molecular diagnostics, gene sequencing, and gene cloning, and the continuous focus of key market players on developing and launching advanced kits.
In 2022, the plasmid DNA isolation segment accounted for the largest share of the market.
Based on type, the global nucleic acid isolation and purification market is segmented into plasmid DNA, total RNA, circulating nucleic acid, genomic DNA, messenger RNA, microRNA, and other nucleic acid isolation and purification types. In 2022, the plasmid DNA isolation and purification segment dominated the global nucleic acid isolation and purification market. The growth of this segment can be attributed to several factors. Firstly, the market benefits from the wide availability of diverse extraction and processing kits specifically designed for plasmid DNA. Additionally, the increasing utilization of plasmid DNA in gene expression profiling and its widespread application in various downstream processes contribute to the segment's expansion.
In 2022, the diagnostics segment accounted for the largest share of the global nucleic acid isolation and purification market.
Based on application, the global nucleic acid isolation and purification market is segmented into personalized medicine, diagnostics, agriculture & animal research, drug discovery & development, and other applications. The diagnostics segment dominated the global nucleic acid isolation and purification market in 2022. Several factors contributed to the segment's prominence including the growing utilization of DNA and RNA isolation in routine sample processing for pathogen identification, the increasing awareness of genomic diagnostics among patients and the improved efficiency of genomics sequencing in disease diagnosis.
In 2022, North America accounted for the largest share of the nucleic acid isolation and purification market.
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2022, North America dominated the global nucleic acid isolation and purification market. The dominance of the regon can be attributed to factors such as presence of key players in the region, increasing R&D spending in pharmaceutical and biotechnology companies, government support, and technological advancements, in the region.
The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 80% and Demand Side 20%
• By Designation: Managers- 45%, CXOs and Directors - 30%, and Executives - 25%
• By Region: North America -37%, Europe -30%, Asia-Pacific -25%, Latin America -5%, Middle East & Africa- 3%
List of Companies Profiled in the Report:
• Thermo Fisher Scientific Inc. (US)
• Merck KGaA (Germany)
• QIAGEN (Germany)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Promega Corporation (US)
• Agilent Technologies, Inc. (US)
• Danaher(US)
• Bio-Rad Laboratories, Inc. (US)
• Illumina, Inc. (US)
• Takara Bio Inc. (Japan)
• New England Biolabs (US)
• Abcam Plc (UK)
• KILPEST India Limited (India)
• Apical Scientific Sdn. Bhd. (Malaysia)
• Endress+Hauser Group Services AG (Switzerland)
• GENAXXON bioscience GmbH (Germany)
• LGC Biosearch Technologies (US)
• Zymo Research Corporation (US)
• Norgen Biotek Corp. (Canada)
• Omega Bio-Tek, Inc. (US)
• FAVORGEN Biotech Corp. (China)
• TIANGEN Biotech (Beijing) Co., Ltd. (China)
• AutoGen Inc. (US)
• PCR Biosystems (UK)
• Biogenuix (India)
Research Coverage: The report comprehensively encompasses in-depth information about the significant factors that impact the growth of the NAIP market, including drivers, restraints, challenges, and opportunities. A meticulous analysis of the leading industry players has been conducted to offer insights into their business overview, solutions, and products. Additionally, the report examines their key strategies, such as partnerships, agreements, new product launches, mergers and acquisitions, and recent developments associated with the NAIP market. Furthermore, the report covers a competitive analysis of emerging startups in the NAIP market ecosystem.
Reasons to Buy the Report
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall NAIP market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (Increasing R&D activities, Technological advancements and increasing automation, Growing demand for molecular diagnostics), restraints (High cost of automated instruments), opportunities (Growth opportunities in emerging economies, Improving regulatory and reimbursement scenario, Molecular diagnostics and personalized medicine), and challenges (Operational barriers and shortage of skilled professionals, and Introduction of alternative technologies) influencing the growth of the nucleic acid isolation and purification market.
• Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new product launches in the nucleic acid isolation and purification market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the nucleic acid isolation and purification market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Nucleic acid isolation and purification market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like Thermo Fisher Scientific Inc. (US), QIAGEN (Germany), Merck KGaA (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Promega Corporation (US), Agilent Technologies, Inc. (US), Danaher(US), Bio-Rad Laboratories, Inc. (US), Illumina, Inc. (US), Takara Bio Inc. (Japan), New England Biolabs (US), Abcam Plc (UK), KILPEST India Limited (India), Apical Scientific Sdn. Bhd. (Malaysia), Endress+Hauser Group Services AG (Switzerland), GENAXXON bioscience GmbH (Germany), LGC Biosearch Technologies (US), Zymo Research Corporation (US), Norgen Biotek Corp. (Canada), Omega Bio-Tek, Inc. (US), FAVORGEN Biotech Corp. (China), TIANGEN Biotech (Beijing) Co., Ltd. (China), AutoGen Inc. (US), PCR Biosystems (UK), and Biogenuix (India).
Table of Contents
1 INTRODUCTION 44
1.1 STUDY OBJECTIVES 44
1.2 MARKET DEFINITION 44
1.2.1 INCLUSIONS & EXCLUSIONS 45
1.3 STUDY SCOPE 46
1.3.1 MARKETS COVERED 46
1.3.2 YEARS CONSIDERED 47
1.4 CURRENCY 47
1.5 LIMITATIONS 47
1.6 STAKEHOLDERS 48
1.7 SUMMARY OF CHANGES 48
1.8 RECESSION IMPACT 49
2 RESEARCH METHODOLOGY 50
2.1 RESEARCH DATA 50
2.1.1 SECONDARY DATA 51
2.1.2 PRIMARY DATA 52
2.2 MARKET SIZE ESTIMATION 53
2.2.1 PRIMARY INSIGHTS 56
2.3 MARKET GROWTH RATE PROJECTIONS 57
2.4 DATA TRIANGULATION APPROACH 59
2.5 STUDY ASSUMPTIONS 60
2.6 RISK ANALYSIS 60
2.7 RECESSION IMPACT ANALYSIS 60
3 EXECUTIVE SUMMARY 63
4 PREMIUM INSIGHTS 68
4.1 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET OVERVIEW 68
4.2 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT AND COUNTRY 69
4.3 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET SHARE, BY TYPE, 2022 69
4.4 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET SHARE, BY PRODUCT, 2022 70
4.5 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET SHARE, BY METHOD, 2022 70
4.6 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET SHARE, BY APPLICATION, 2022 71
4.7 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET SHARE, BY END USER, 2022 71
4.8 GEOGRAPHICAL SNAPSHOT OF NUCLEIC ACID ISOLATION AND PURIFICATION MARKET 72
5 MARKET OVERVIEW 73
5.1 INTRODUCTION 73
5.2 MARKET DYNAMICS 73
5.2.1 DRIVERS 74
- 5.2.1.1 Increasing R&D activities 74
- 5.2.1.2 Technological advancements and increasing automation 76
- 5.2.1.3 Growing demand for molecular diagnostics 76
5.2.2 RESTRAINTS 78
- 5.2.2.1 High cost of automated instruments 78
5.2.3 OPPORTUNITIES 79
- 5.2.3.1 Growth opportunities in emerging economies 79
- 5.2.3.2 Improving regulatory and reimbursement scenario 80
- 5.2.3.3 Molecular diagnostics and personalized medicine 81
5.2.4 CHALLENGES 81
- 5.2.4.1 Operational barriers and shortage of skilled professionals 81
- 5.2.4.2 Introduction of alternative technologies 82
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 82
5.4 PATENT ANALYSIS 83
5.5 VALUE CHAIN ANALYSIS 84
5.6 SUPPLY CHAIN ANALYSIS 85
5.7 ECOSYSTEM ANALYSIS 86
5.8 KEY CONFERENCES & EVENTS IN 2023-2024 88
5.9 PRICING ANALYSIS 89
5.9.1 AVERAGE SELLING PRICE, BY PRODUCT 89
5.9.2 AVERAGE SELLING PRICE, BY REGION 90
5.10 TECHNOLOGY ANALYSIS 90
5.11 PORTER’S FIVE FORCES ANALYSIS 91
5.11.1 THREAT OF NEW ENTRANTS 92
5.11.2 THREAT OF SUBSTITUTES 92
5.11.3 BARGAINING POWER OF SUPPLIERS 92
5.11.4 BARGAINING POWER OF BUYERS 92
5.11.5 INTENSITY OF COMPETITIVE RIVALRY 92
5.12 REGULATORY ANALYSIS 93
5.12.1 REGULATORY BODIES 94
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 96
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 96
5.13.2 BUYING CRITERIA FOR NUCLEIC ACID ISOLATION AND PURIFICATION PRODUCTS 97
6 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT 98
6.1 INTRODUCTION 99
6.2 KITS 99
6.2.1 KITS TO ACCOUNT FOR LARGEST SHARE OF MARKET DURING FORECAST PERIOD 99
6.3 REAGENTS 103
6.3.1 AVAILABILITY OF READY-TO-USE REAGENTS TO DRIVE GROWTH 103
6.4 INSTRUMENTS 106
6.4.1 AUTOMATIC INSTRUMENTS 110
- 6.4.1.1 Benefits of automatic instruments to drive growth 110
6.4.2 MANUAL INSTRUMENTS 113
- 6.4.2.1 Growing demand for nucleic acid isolation and purification in research and clinical applications to drive growth 113
7 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD 117
7.1 INTRODUCTION 118
7.2 MAGNETIC BEAD-BASED ISOLATION AND PURIFICATION 118
7.2.1 MAGNETIC BEAD-BASED ISOLATION AND PURIFICATION SEGMENT TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 118
7.3 REAGENT-BASED ISOLATION AND PURIFICATION 121
7.3.1 REAGENT-BASED ISOLATION AND PURIFICATION SEGMENT TO REGISTER STEADY GROWTH DURING FORECAST PERIOD 121
7.4 COLUMN-BASED ISOLATION AND PURIFICATION 124
7.4.1 GROWING POPULARITY OF COLUMN-BASED ISOLATION AND PURIFICATION IN CURRENT KITS TO BOOST MARKET 124
7.5 OTHER ISOLATION AND PURIFICATION METHODS 127
8 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE 131
8.1 INTRODUCTION 132
8.2 PLASMID DNA ISOLATION AND PURIFICATION 132
8.2.1 PLASMID DNA ISOLATION AND PURIFICATION TO ACCOUNT FOR LARGEST SHARE OF MARKET 132
8.3 TOTAL RNA ISOLATION AND PURIFICATION 136
8.3.1 WIDE USE OF TOTAL RNA ISOLATION AND PURIFICATION FOR RESEARCH AND DIAGNOSTIC APPLICATIONS TO BOOST MARKET 136
8.4 GENOMIC DNA ISOLATION AND PURIFICATION 139
8.4.1 IMPORTANCE OF GENOMIC DNA ISOLATION IN GENETIC-BASED TESTS TO SUPPORT GROWTH 139
8.5 MESSENGER RNA ISOLATION AND PURIFICATION 142
8.5.1 ROLE PLAYED BY MESSENGER RNA ISOLATION AND PURIFICATION IN GENE EXPRESSION AND TRANSCRIPTOMICS TO DRIVE GROWTH 142
8.6 CIRCULATING NUCLEIC ACID ISOLATION AND PURIFICATION 145
8.6.1 ABILITY OF CIRCULATING NAIP TO ENABLE COLLECTION OF GENETIC INFORMATION FROM BODY FLUIDS TO BOOST ADOPTION 145
8.7 MICRORNA ISOLATION AND PURIFICATION 148
8.7.1 GROWING APPLICATIONS OF MICRORNA ISOLATION AND PURIFICATION IN DRUG DEVELOPMENT RESEARCH TO FUEL GROWTH 148
8.8 OTHER NUCLEIC ACID ISOLATION AND PURIFICATION TYPES 151
9 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION 154
9.1 INTRODUCTION 155
9.2 DIAGNOSTICS 155
9.2.1 DIAGNOSTIC APPLICATIONS TO DOMINATE MARKET DURING FORECAST PERIOD 155
9.3 DRUG DISCOVERY & DEVELOPMENT 158
9.3.1 POTENTIAL OF NAIP TO HELP IN DEVELOPMENT OF DRUGS FOR RARE DISEASES TO BOOST MARKET 158
9.4 PERSONALIZED MEDICINE 162
9.4.1 RISING INCIDENCE OF CANCER AND INCREASING RESEARCH AND FUNDING TO DRIVE GROWTH 162
9.5 AGRICULTURE & ANIMAL RESEARCH 165
9.5.1 FAVORABLE FUNDING SCENARIO TO SUPPORT MARKET GROWTH 165
9.6 OTHER APPLICATIONS 169
10 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER 173
10.1 INTRODUCTION 174
10.2 HOSPITALS & DIAGNOSTIC CENTERS 174
10.2.1 RISING FOCUS ON PERSONALIZED MEDICINE IN HOSPITALS TO DRIVE MARKET GROWTH 174
10.3 ACADEMIC & GOVERNMENT RESEARCH INSTITUTES 178
10.3.1 INCREASE IN RESEARCH INTENSITY TO DRIVE USAGE OF NUCLEIC ACID ISOLATION AND PURIFICATION SYSTEMS 178
10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 182
10.4.1 INCREASING NUMBER OF RESEARCH PROJECTS IN GENOMICS AND RELATED AREAS TO DRIVE SEGMENT GROWTH 182
10.5 CONTRACT RESEARCH ORGANIZATIONS 186
10.5.1 CONTRACT RESEARCH ORGANIZATIONS TO REGISTER STEADY GROWTH DURING FORECAST PERIOD 186
10.6 OTHER END USERS 189
11 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY REGION 193
11.1 INTRODUCTION 194
11.2 NORTH AMERICA 194
11.2.1 US 199
- 11.2.1.1 Government and private funding to support market growth 199
11.2.2 CANADA 202
- 11.2.2.1 Growing investments in genomics to boost market demand 202
11.2.3 NORTH AMERICA: RECESSION IMPACT 205
11.3 EUROPE 206
11.3.1 GERMANY 209
- 11.3.1.1 Germany to dominate market in Europe 209
11.3.2 UK 213
- 11.3.2.1 Government support for research through investments, funds, and grants to support market growth 213
11.3.3 FRANCE 216
- 11.3.3.1 High cancer burden to drive market growth 216
11.3.4 ITALY 220
- 11.3.4.1 Government support to drive market growth in Italy 220
11.3.5 SPAIN 223
- 11.3.5.1 High adoption of advanced diagnostic technologies to drive market growth in Spain 223
11.3.6 REST OF EUROPE 226
11.3.7 EUROPE: RECESSION IMPACT 229
11.4 ASIA PACIFIC 230
11.4.1 CHINA 235
- 11.4.1.1 China to register highest growth in nucleic acid isolation and purification market in Asia Pacific region 235
11.4.2 JAPAN 238
- 11.4.2.1 Growing number of conferences & workshops to drive market growth 238
11.4.3 INDIA 241
- 11.4.3.1 Focused initiatives in pharmaceutical & biotechnology industries to drive market growth 241
11.4.4 SOUTH KOREA 244
- 11.4.4.1 Support from governments to drive market in region 244
11.4.5 REST OF ASIA PACIFIC (ROAPAC) 247
11.4.6 ASIA PACIFIC: RECESSION IMPACT 251
11.5 LATIN AMERICA 251
11.5.1 BRAZIL 255
- 11.5.1.1 Brazil to dominate LATAM market 255
11.5.2 MEXICO 258
- 11.5.2.1 Favorable trade agreements to support imports and improve access to NAIP instruments in Mexico 258
11.5.3 REST OF LATIN AMERICA 261
11.5.4 LATIN AMERICA: RECESSION IMPACT 264
11.6 MIDDLE EAST & AFRICA 265
11.6.1 MIDDLE EAST 268
- 11.6.1.1 Growing focus on molecular diagnostics and research to drive market 268
11.6.2 AFRICA 271
- 11.6.2.1 Government support for research studies to fuel growth 271
11.6.3 MIDDLE EAST & AFRICA: RECESSION IMPACT 274
12 COMPETITIVE LANDSCAPE 275
12.1 INTRODUCTION 275
12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 275
12.3 REVENUE ANALYSIS 277
12.4 MARKET SHARE ANALYSIS 278
12.5 COMPANY EVALUATION MATRIX 280
12.5.1 STARS 281
12.5.2 EMERGING LEADERS 281
12.5.3 PERVASIVE PLAYERS 281
12.5.4 PARTICIPANTS 281
12.5.5 COMPANY FOOTPRINT ANALYSIS 283
- 12.5.5.1 Company footprint 283
- 12.5.5.2 Company product footprint 284
- 12.5.5.3 Company regional footprint 285
12.6 START-UP/SME EVALUATION MATRIX 287
12.6.1 PROGRESSIVE COMPANIES 287
12.6.2 RESPONSIVE COMPANIES 287
12.6.3 DYNAMIC COMPANIES 287
12.6.4 STARTING BLOCKS 287
12.6.5 COMPETITIVE BENCHMARKING 289
12.7 COMPETITIVE SCENARIO AND TRENDS 291
12.7.1 PRODUCT LAUNCHES 291
12.7.2 DEALS 292
12.7.3 OTHER DEVELOPMENTS 293
13 COMPANY PROFILES 294
13.1 MAJOR PLAYERS 294
13.1.1 THERMO FISHER SCIENTIFIC INC 294
13.1.2 QIAGEN 312
13.1.3 F. HOFFMANN-LA ROCHE LTD 322
13.1.4 MERCK KGAA 327
13.1.5 PROMEGA CORPORATION 334
13.1.6 AGILENT TECHNOLOGIES, INC 338
13.1.7 DANAHER 341
13.1.8 BIO-RAD LABORATORIES, INC 346
13.1.9 ILLUMINA, INC 349
13.1.10 TAKARA BIO INC 352
13.1.11 NEW ENGLAND BIOLABS 357
13.1.12 ABCAM PLC 361
13.2 OTHER COMPANIES 364
13.2.1 KILPEST INDIA LIMITED 364
13.2.2 APICAL SCIENTIFIC SDN. BHD 365
13.2.3 ENDRESS+HAUSER GROUP SERVICES AG 366
13.2.4 GENAXXON BIOSCIENCE GMBH 367
13.2.5 LGC BIOSEARCH TECHNOLOGIES 368
13.2.6 ZYMO RESEARCH CORPORATION 369
13.2.7 NORGEN BIOTEK CORP 372
13.2.8 OMEGA BIO-TEK, INC 373
13.2.9 FAVORGEN BIOTECH CORPORATION 375
13.2.10 TIANGEN BIOTECH(BEIJING)CO., LTD 376
13.2.11 AUTOGEN INC 377
13.2.12 PCR BIOSYSTEMS 379
13.2.13 BIOGENUIX 380
14 APPENDIX 381
14.1 DISCUSSION GUIDE 381
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 385
14.3 CUSTOMIZATION OPTIONS 387
14.4 RELATED REPORTS 387
14.5 AUTHOR DETAILS 388